Profile data is unavailable for this security.
About the company
Bangkok Lab and Cosmetic Public Company Limited is a Thailand-based producer and researcher of health products. The principal activities of the Company and subsidiaries are engaged in the manufacturing and distributing of pharmaceuticals and medicinal chemical products for humans and animals. It operates through pharmaceuticals and medicinal chemical products segment. Its products include ZENZERA 200 SUSPENSION, ZENZERA, SYNOVAR UC40, RADIARA, PROCEMINE, FANGO-B, EMBLICOF COUGH MIXTURE, CLINIGEL STERILE, RAQUA FIBROTA, RAQUA COLLAGEN, SYNOVAR UC, SYNOVAR POWDER, NACOXIB, LUTI-BERRY MIXED, ZIGA GEL (orange), ZERTINE SYRUP, VIZO Cream, SPORAXYL CREAM, NORAPHEN, MURHINOL-250 SYRUP, NORFLOXYL 400, NOCID, MURHINOL-250 SYRUP, MUCOBROX, GYNOSTEN CREAM, and GYNOSTEN 500, AROTIKA COOL GEL, ALLERAX-FC, AROTIKA RUB LOTION (SPRAY), Calza c Dietary Supplement, Calza PLUS POWDER Dietary, Calza-750 TAB FC, and others. Its subsidiaries include Bangkok Drug Co., Ltd., and Pharma Alliance Co., Ltd.
- Revenue in THB (TTM)1.43bn
- Net income in THB156.29m
- Incorporated2022
- Employees698.00
- LocationBangkok Lab and Cosmetic PCL48/1 Moo 5 Nongshaesao Rd.Namphu, Mueang RatchaburiRATCHABURI 70000ThailandTHA
- Phone+66 32719900
- Fax+66 32719917
- Websitehttps://bangkoklab.co.th/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nano Mrna Co Ltd | 30.98m | -178.30m | 2.85bn | 17.00 | -- | 3.64 | -- | 91.95 | -11.10 | -11.10 | 1.93 | 48.61 | 0.025 | 59.02 | 9.66 | -- | -14.37 | -24.16 | -15.59 | -25.17 | 81.88 | 84.69 | -575.61 | -600.70 | 9.17 | -- | 0.2448 | -- | -32.98 | -22.88 | 40.50 | -- | -- | -- |
| RaQualia Pharma Inc | 498.17m | -57.92m | 2.94bn | 67.00 | -- | 2.14 | -- | 5.90 | -11.72 | -11.72 | 100.79 | 277.21 | 0.247 | 2.76 | 3.03 | 32,526,720.00 | -2.87 | 2.13 | -3.18 | 2.26 | 88.70 | 88.49 | -11.63 | 5.32 | 3.53 | -- | 0.4031 | 0.00 | -34.85 | 20.62 | -144.74 | -- | 0.0967 | -- |
| Bangkok Lab and Cosmetic PCL | 1.43bn | 156.29m | 2.94bn | 698.00 | 18.04 | 1.82 | 13.63 | 2.05 | 0.2717 | 0.2717 | 2.50 | 2.69 | 0.8267 | 2.44 | 4.35 | 2,054,923.00 | 9.32 | 6.01 | 14.01 | 13.28 | 31.30 | 27.33 | 11.28 | 5.68 | 3.48 | 9.80 | 0.1233 | -- | 8.50 | 17.54 | 15.65 | 51.84 | 19.54 | -- |
| Inter Pharma PCL | 1.79bn | 26.52m | 2.99bn | 282.00 | 112.73 | 1.55 | 22.57 | 1.67 | 0.0438 | 0.0438 | 2.96 | 3.19 | 0.5961 | 3.31 | 4.90 | -- | 1.05 | 5.54 | 1.34 | 7.20 | 36.43 | 42.85 | 1.75 | 8.01 | 1.71 | 2.72 | 0.1529 | 33.15 | 16.93 | 41.18 | -57.28 | 11.34 | 73.30 | -- |
| ReproCell Inc | 554.75m | -7.18m | 2.99bn | 96.00 | -- | 1.56 | 2,297.01 | 5.39 | -0.3466 | -0.3466 | 28.34 | 93.45 | 0.2788 | 5.41 | 5.60 | 25,279,340.00 | -0.3609 | -7.35 | -0.3932 | -8.00 | 46.19 | 39.83 | -1.29 | -27.16 | 10.54 | -- | 0.00 | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
| Recce Pharmaceuticals Ltd | 167.04m | -277.46m | 3.00bn | -- | -- | 228.80 | -- | 17.96 | -0.0637 | -0.0637 | 0.0385 | 0.0026 | 1.68 | -- | 52.84 | -- | -279.04 | -110.82 | -985.91 | -139.61 | -- | -- | -166.11 | -391.79 | -- | -24.07 | 0.2712 | -- | 39.53 | 27.79 | -19.03 | -- | -26.31 | -- |
| Sakar Healthcare Ltd | 676.43m | 51.48m | 3.02bn | 297.00 | 56.60 | 2.61 | 23.08 | 4.47 | 5.57 | 5.57 | 73.21 | 120.61 | 0.423 | 3.88 | 7.13 | -- | 3.22 | 5.26 | 3.81 | 6.28 | 45.43 | 44.13 | 7.60 | 10.12 | 0.743 | 2.68 | 0.2322 | -- | 14.99 | 17.58 | -8.53 | 11.76 | 19.05 | -- |
| Holder | Shares | % Held |
|---|---|---|
| MFC Asset Management Public Co., Ltd. (Investment Management)as of 28 Dec 2023 | 3.99m | 0.67% |
